Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Steven Trifilio; Zheng Zhou; Jessica Altman; Olga Frankfurt; Mihaela Pantiru; Jayesh Mehta

doi:10.1016/j.leukres.2013.05.006

Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Steven Trifilio^*, Zheng Zhou, Jessica Altman, Olga Frankfurt, Mihaela Pantiru, Jayesh Mehta

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

Original language	English (US)
Pages (from-to)	872-876
Number of pages	5
Journal	Leukemia Research
Volume	37
Issue number	8
DOIs	https://doi.org/10.1016/j.leukres.2013.05.006
State	Published - Aug 2013

Keywords

Acute myeloid leukemia
Complete remission
Cyclophosphamide
Etoposide

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2013.05.006

Cite this

@article{bb063402531c4927a8bd13289e00685f,

title = "Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia",

abstract = "Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.",

keywords = "Acute myeloid leukemia, Complete remission, Cyclophosphamide, Etoposide",

author = "Steven Trifilio and Zheng Zhou and Jessica Altman and Olga Frankfurt and Mihaela Pantiru and Jayesh Mehta",

year = "2013",

month = aug,

doi = "10.1016/j.leukres.2013.05.006",

language = "English (US)",

volume = "37",

pages = "872--876",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

number = "8",

}

Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia. / Trifilio, Steven; Zhou, Zheng; Altman, Jessica ; Frankfurt, Olga; Pantiru, Mihaela; Mehta, Jayesh.

In: Leukemia Research, Vol. 37, No. 8, 08.2013, p. 872-876.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

AU - Trifilio, Steven

AU - Zhou, Zheng

AU - Altman, Jessica

AU - Frankfurt, Olga

AU - Pantiru, Mihaela

AU - Mehta, Jayesh

PY - 2013/8

Y1 - 2013/8

N2 - Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

AB - Dose-intense etoposide-cyclophosphamide (D-I ECy) without stem cell transplantation has been used in salvage regimens for the treatment of resistant acute myeloid leukemia(AML). Previous D-I ECy studies classified AML according to FAB-criteria, before cytogenetic risk was found to be a major determinant of prognosis. Currently the influence of karyotype on response to D-I ECy is unknown. Thus, an observational study was conducted in thirty four patients treated with D-I ECy for resistant AML. The results show this regimen is moderately effective in achieving CR in relapsed AML patients, including those with age >60 and poor cytogenetic risk category.

KW - Acute myeloid leukemia

KW - Complete remission

KW - Cyclophosphamide

KW - Etoposide

UR - http://www.scopus.com/inward/record.url?scp=84879780788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879780788&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2013.05.006

DO - 10.1016/j.leukres.2013.05.006

M3 - Article

C2 - 23759246

AN - SCOPUS:84879780788

VL - 37

SP - 872

EP - 876

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 8

ER -

Dose-intense etoposide-cyclophosphamide without stem cell transplantation for patients with intermediate and high cytogenetic risk primary refractory and relapsed acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this